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This study investigated green tea catechins in plasma and urine and chronic disease 26 
biomarkers. We hypothesized that plasma and urinary concentration of green tea catechins 27 
are associated with cardiovascular disease and diabetes biomarkers. First void urine and 28 
fasting plasma samples were collected from 57 generally healthy females aged 38-73 (mean 29 
52±8) years recruited in Himeji, Japan. The concentrations of plasma and urinary green tea 30 
catechins were determined by liquid chromatography coupled with mass tandem 31 
spectrometer. LDL-cholesterol, HDL-cholesterol, triglyceride, glucose, insulin, glycated 32 
haemoglobin (HbA1c), and C-reactive protein (CRP) in plasma/serum samples were analyzed 33 
by a commercial diagnostic laboratory. Statistical associations were assessed using Spearman 34 
correlation coefficients. The results showed weak associations between plasma total catechin 35 
and triglyceride (r=-0.30) and LDL-cholesterol (r=-0.28), while plasma (-)-epigallocatechin-36 
3-gallate (EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin-3-gallate (ECG), and (-)-37 
epicatechin (EC) exhibited weak to moderate associations with triglyceride or LDL-38 
cholesterol, but little associations with HDL-cholesterol, body fat and body mass index 39 
(BMI) were evident. Urinary total catechin was weakly associated with triglyceride (r=-0.19) 40 
and LDL-cholesterol (r=-0.15), whereas urinary EGCG (r=-0.33) EGC (r=-0.23) and ECG 41 
(r=-0.33) had weak to moderate correlations with triglyceride, and similarly with body fat and 42 
BMI. Both plasma (r=-0.24) and urinary (r=-0.24) total catechin, as well as individual 43 
catechins, were weakly associated with HbA1c. Plasma total and individual catechins were 44 
weakly to moderately associated with CRP, but not the case for urinary catechins. In 45 
conclusion, we found weak to moderate associations between plasma and urinary green tea 46 
catechin concentrations and plasma biomarkers of cardiovascular disease and diabetes. 47 
 48 
Keywords : biomarker; cardiovascular disease; catechin; diabetes; green tea  49 
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1. Introduction 50 
During the past two decades, the preventative role of green tea has been reported in certain 51 
chronic diseases such as cardiovascular disease (CVD) and type-2 diabetes [1]. A recent large 52 
cohort study involving 76,979 individuals aged 40-79 years in Japan observed that green tea 53 
consumption was associated with lower CVD mortality by up to 38% [2]. Increased tea 54 
consumption is also related to an attenuated risk of cardiac death, coronary heart disease, 55 
intracerebral hemorrhage, and cerebral infarction according to a systematic review and meta-56 
analysis of prospective observational studies [3]. In a study of subjects with myocardial 57 
infarction, green tea consumption significantly reduced serum concentrations of LDL, C-58 
reactive protein (CRP) and interleukin (IL)-6 [4]. Similarly, a dose-response meta-analysis of 59 
16 cohort studies found a linear inverse association between tea consumption and risk of 60 
type-2 diabetes [5]. However, the mechanisms by which green tea reduces the risk of CVD 61 
and diabetes are not fully understood. 62 
  63 
Both in vivo and in vitro experimental studies have suggested that the beneficial effects of 64 
green tea may be attributed to its high content of anti-inflammatory/anti-oxidative 65 
polyphenols. The main phenolic compounds in green tea are catechins, including (-)-66 
epigallocatechin-3-gallate (EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin-3-gallate 67 
(ECG), and (-)-epicatechin (EC), with EGCG being the highest accounting for 60-65% of the 68 
entire catechin content [6]. Among these four catechins, most studies focused on the effect of 69 
EGCG. For example, EGCG was found to reduce blood pressure and myocardial infarct size 70 
and improve endothelial function and insulin sensitivity in a rat model of cardiovascular 71 
disorder [7]. Rodent models of obesity/diabetes similarly demonstrated significant reductions 72 
in body fat and plasma cholesterol, attenuated insulin resistance, decreased blood glucose, 73 
and improved insulin sensitivity by EGCG [8-10]. On the other hand, only one study showed 74 
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that EC reduced plasma glucose in streptozotocin induced insulin resistant rats within 6 days 75 
[11]. Moreover, the relationships between green tea catechins in plasma and urine, and 76 
biomarkers of CVD and diabetes in healthy population, have never been reported in the 77 
literature.  78 
 79 
In this study, we hypothesized that plasma and urinary concentration of green tea catechins 80 
are associated with the CVD and diabetes biomarkers in generally healthy subjects. Our 81 
objectives were to determine the concentrations of EGCG, EGC, ECG and EC in plasma and 82 
urine of healthy Japanese women, and to assess their association with the plasma biomarkers 83 
of CVD and diabetes. 84 
 85 
2. Methods and materials 86 
2.1. Subjects recruitment 87 
Subjects were recruited from Tsunashimakai Kosei Hospital and University of Hyogo in 88 
Himeji, located in Hyogo Prefecture of central Japan, during April-August 2014. After 89 
screening for inclusion criteria (female aged 35 years or over), individuals currently on 90 
prescription for a chronic condition or had modified their diet within the past year were 91 
excluded. The study purpose and procedure were explained to the subjects before obtaining 92 
their informed written consent. The recruitment process terminated when the target sample of 93 
60 volunteers was met. The study protocol was approved by the Curtin University Human 94 
Research Ethics Committee (approval no. 4649) and University of Hyogo Research Ethics 95 
Committee (approval no. 068). 96 
 97 
2.2. Urine and plasma sample collection 98 
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Participants were instructed to fast overnight for more than 8 hours before collecting their 99 
first morning void in a supplied container. Fasting blood samples were taken by a qualified 100 
phlebotomist and collected in a serum separator tube and a heparin tube. Plasma, serum and 101 
urine samples were then stored at -80 
◦
C until analysis. Anthropometric and blood pressure 102 
measurements were also taken prior to venous blood sampling, along with basic demographic 103 
characteristics. A body composition scale (Tanita, Tokyo, Japan) was used to measure body 104 
weight and body fat percentage. 105 
 106 
2.3. Analysis of green tea catechins 107 
The concentrations of EGCG, ECG, EGC, and EC in plasma and urine were determined with 108 
a highly sensitive method using high performance liquid chromatography (HPLC; Agilent 109 
1100LC with binary pump) coupled with tandem mass spectrometer (MS/MS) (Applied 110 
Biosystems Sciex API 3000), as described previously with some minor modifications [12-111 
15]. Briefly, 500 µl of plasma samples were mixed with 20 µl of 10% ascorbic acid (w/w in 112 
water) and 100 µl of 1% sulfatase H-1 (w/w in sodium acetate buffer, pH 5, Sigma S9626, 113 
≥10 unit/mg with β-glucuronidase ≥300 unit/mg). Following incubation at 37
◦
C for 45 114 
minutes to allow enzymatic hydrolysis, 2.5 µl of 40 µM ehyl gallate was added as an internal 115 
standard. Subsequently, deconjugated and free catechins were extracted using 500 µl of 0.1% 116 
formic acid in ethyl acetate. The extraction process was repeated three times, and the pooled 117 
extract was evaporated under vacuum (Tomy CC-105 centrifugal concentrator and Eyel4 118 
Unitrap UT-2000 evaporator). The samples were then reconstituted in a buffer (15% 119 
acetonitrile and 0.1% formic acid), and centrifuged at 15,000 xg at 4
◦
C for 5 min. A total of 120 




Five µl of samples were injected into Develosil ODS-SR C18, 5 µm, 2 × 150 mm column 123 
(Nomura Chemical) with binary gradient of 0.1% formic acid in ultrapure water (A) and 124 
0.1% formic acid in acetonitrile (B) at a constant flow rate of 0.2 ml/min. The gradient 125 
program began at 15% solvent B, increasing to 25% by 10 min and to 50% by 14 min, before 126 
returning to 15% which was held for 10 min. The total method duration was 25 min. The 127 
mass spectrometer was operated with electrospray ionization in negative mode. The ion spray 128 
potential was -4500 V, and the source temperature was set at 450
◦
C. Supplementary Table 1 129 
presents values for the m/z ratio and detection limit. 130 
 131 
EGCG, EGC, ECG, EC and ethyl gallate, purchased from Sigma-Aldrich, were used as a 132 
standard. The peak of each phenolic compound was identified based on a comparison of its 133 
retention times and mass spectral data with the corresponding standard and published data 134 
[12-15], using the Analyst v1.6 software (ABSciex); see Figure 1. All samples were 135 
measured in duplicates. 136 
 137 
2.4. Measurement of CVD and diabetic biomarkers 138 
Plasma or serum concentrations of triglycerides, LDL-cholesterol, HDL-cholesterol, glucose, 139 
glycated haemoglobin (HbA1c), insulin and CRP were measured by a commercial diagnostic 140 
laboratory (Falco Biosystems, Hyogo, Japan). 141 
 142 
2.5. Statistical analyses 143 
All data were managed via Microsoft Excel. ‘Total catechin’ was defined as the sum of 144 
EGCG, EGC, ECG and EC. Normality of the data was assessed using a combination of 145 
graphical and statistical methods including boxplot, histogram, normal probability plot and 146 
Lilliefors test. In view of the observed non-normal distributions of the catechin variables, we 147 
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applied the nonparametric Spearman’s rank correlation to ascertain the strength of the 148 
association with CVD and diabetes biomarkers consistently for all variables (Figure 2). 149 
Statistical significance was taken at p<0.05. 150 
 151 
The sample size required (n=57 participants) was set to detect a moderate association of 0.37 152 
between green tea catechins and markers of chronic diseases, with 80% power at 5% level of 153 
statistical significance using the Stata software Release 13 (StataCorp. 2013. College Station, 154 
TX). Initially 60 subjects were recruited to allow for dropouts, and three consented 155 
participants subsequently withdrawn from the study due to personal reasons. 156 
 157 
3. Results 158 
3.1. Sample characteristics 159 
For the 57 healthy women who completed the study, their age ranged between 38 and 73 160 
(mean 52±8) years. Their mean body mass index (BMI) was 22.5±4.1 kg/m
2 
, with mean 161 
weight 54.2±9.0 kg and body fat 24.6±6.4 %. Table 1 summarizes the demographic 162 
characteristics of the participants. Mean plasma and urinary concentrations of EGCG, EGC, 163 
ECG and EC, as well as plasma concentrations of triglyceride, LDL-cholesterol, HDL-164 
cholesterol, fasting glucose, HbA1c, insulin and CRP are presented in Supplementary Table 2 165 
and Supplementary Table 3. 166 
 167 
3.2. Association between plasma and urinary catechins and CVD biomarkers 168 
Table 2 gives the Spearman’s correlation coefficients between plasma and urinary catechins 169 
and CVD biomarkers. Higher plasma total catechin, EGCG and EGC were weakly associated 170 
with lower triglyceride levels, while ECG showed moderate association. Urinary 171 
concentration of EGCG and ECG had moderate negative associations with triglyceride, but 172 
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only weak association was observed for EGC in urine. Plasma total catechin, as well as 173 
individual catechins, consistently exhibited weak negative associations with LDL-cholesterol, 174 
but not the case for urinary catechins. Neither plasma nor urinary catechins appeared to be 175 
associated with HDL-cholesterol. There were some weak negative associations found 176 
between body fat percentage and urinary EGCG and ECG, and similarly between BMI and 177 
ECG in urine.  178 
 179 
3.3. Association between plasma and urinary catechins and diabetes biomarkers 180 
Table 3 shows the Spearman’s correlation coefficients between plasma and urinary catechins 181 
and biomarkers of diabetes. HbA1c appeared to be negatively associated with total catechin, 182 
EGCG, ECG and EC for both plasma and urine, but the strength of the apparent associations 183 
was weak. Lower CRP was moderately associated with higher plasma concentrations of EGC 184 
and EC, but the associations were much weaker for plasma total catechin, EGCG and ECG, 185 
and all urinary catechins. For plasma levels of fasting glucose and insulin, no evidence of 186 
association was found with plasma and urinary catechins. 187 
 188 
4. Discussion 189 
Epidemiological studies have shown that the consumption of green tea can reduce CVD risk 190 
and improve plasma lipid profile [1, 4]. Similarly, clinical trials and animal intervention 191 
studies demonstrated significant reduction of plasma LDL and triglyceride with co-192 
supplementation of green tea extract, and more specifically with EGCG ingestion by women 193 
[16, 17]. Weight loss, decreases in BMI and waist and hip circumferences, were also reported 194 
through EGCG supplementation [18, 19]. In a rat model of type-1 diabetes, an administration 195 
of green tea extract reduced circulating total cholesterol level and body weight [20]. 196 
Consistent with previous findings, our results showed negative associations between the 197 
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concentration of green tea phenolic compounds in plasma, and LDL-cholesterol and 198 
triglycerides, but to less extent for urinary green tea catechins. Some evidence of relationship 199 
was also found between the urinary catechins and body fat and BMI, though the observed 200 
associations were rather weak. Overall, the data suggest the potential of using plasma and 201 
urinary catechins as biomarkers of green tea consumption, and thereafter to estimate the CVD 202 
risk.  203 
 204 
The underlying mechanisms by which green tea catechins improve plasma lipid profile and 205 
contribute to weight loss are not fully understood. A number of studies have suggested the 206 
interaction of tea catechins with lipid digestion and absorption. A clinical trial demonstrated 207 
decreased lipid digestion and absorption by green tea extract with 
13
C-labelled mixed 208 
triglyceride breath test [21]. In vitro studies showed that substantially inhibited gastric and 209 
pancreatic lipase activities reduce the lipolysis of triglyceride by green tea catechins [22]. 210 
Moreover, in high-fat fed rodents, EGCG suppressed triglyceride absorption by attenuating 211 
pancreatic lipase which resulted in significant weight loss [23]. Another study reported that 212 
EGCG can inhibit pancreatic phospholipase A2, leading to the inhibition of luminal 213 
phosphatidylcholine hydrolysis, a process critical to the intestinal lipid digestion and 214 
absorption [24, 25]. Some investigations also found that green tea catechins can modulate the 215 
emulsification of lipids in the intestinal lumen. A typical daily intake of green tea increased 216 
the particle size of lipid emulsion and decreased the surface area, which consequently 217 
resulted in the retarded hydrolysis of fat by pancreatic lipase [26, 27]. 218 
 219 
Another potential mechanism is the interaction of green tea polyphenols with lipid 220 
metabolism since high levels of catechins were found postprandially in the liver, the main 221 
organ responsible for lipogenesis. By using human hepatic cell line of HepG2, EGCG 222 
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significantly reduced its lipogenesis through enhanced phosphorylated AMP-activated 223 
protein kinase (AMPK) expression [28]. In vivo studies of mice consistently demonstrated a 224 
significant increase in AMPK activity and phosphorylation by an oral administration of 225 
EGCG [29, 30]. Another study showed that an EGCG-free fraction derived from green tea 226 
significantly reduced the hepatic gene expression of lipogenic enzymes and proteins such as 227 
acetyl-CoA carbosylase and sterol regulatory element-binding protein-1c [31]. 228 
 229 
Because the bioavailability of catechins, particularly EGCG at 0.1%, is extremely low and 230 
varies between individuals, the plasma concentration of catechins may efficiently and 231 
accurately reflect the net exposure to the lipogenic organs [6]. On the other hand, the 232 
availability of catechins in the intestinal lumen for the digestion and absorption interaction 233 
may be reflected by its urinary excretion. The consistent association of plasma lipid profile 234 
with both plasma and urinary green tea catechins, as observed in this study, suggest that both 235 
interactions in the lipogenic organs and intestinal lumen of the catechins may equally 236 
contribute to the modulation of plasma lipid concentration, and thereafter to the CVD risk. 237 
 238 
In addition to the cardio-protective properties, green tea catechins can exert some anti-239 
diabetic effects including lowered blood glucose, increased insulin sensitivity and suppressed 240 
systemic low-grade inflammation. In a clinical randomized controlled trial, EGCG 241 
supplementation for 8 weeks moderately reduced plasma glucose and insulin [17], while the 242 
supplementation of 200 mg/kg green tea extract for 4 weeks significantly reduced the serum 243 
glucose in type 1 diabetic rats[20]. In rats fed with high sucrose and cholesterol diet, their 244 
serum glucose and insulin levels significantly decreased after supplementation of EGCG 245 
[32]. In addition, significantly reduced peripheral inflammation by EGCG co-246 
supplementation with a high fat diet for 25 weeks was found in Goto-Kakizaki non-obese 247 
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type 2 diabetic rats [33]. In the present study, we found weak to moderate inverse 248 
associations between plasma catechins and HbA1c and CRP, but only HbA1c for urinary 249 
catechins.  250 
 251 
Similar to the effects on lipids, the underlying mechanisms of glucose lowering effects of 252 
green tea catechins may initiate with their intestinal digestion and absorption. In a clinical 253 
trial, an acute ingestion of catechin-rich green tea improved postprandial glucose status [34]. 254 
In vitro studies reported a significant downregulation of gastrointestinal digestive enzymes 255 
necessary for starch digestion including α-amylase and α-glucosidase by EGCG [35, 36]. 256 
Additionally, inhibition of glucose uptake by green tea catechin-treated human intestinal 257 
absorptive cell line of caco-2 was demonstrated through suppressed expression of glucose 258 
transporters that are responsible for the enterocytic glucose uptake, including sodium-259 
dependent glucose transporter 1, glucose transporter (GLUT) 2 and GLUT5 [37, 38]. On the 260 
other hand, in the liver, EGCG enhanced the phosphorylation of Ser9 glycogen synthase 261 
kinase and Ser641 glycogen synthase [28]. Moreover, in insulin resistant HepG2 hepatocytes, 262 
EGCG improved insulin-stimulated down signaling, by reducing the Ser307 phosphorylation 263 
of insulin receptor substrate-1 through activated AMPK [39]. Likewise, in muscle cell line of 264 
rat L6, EGCG upregulated the insulin-dependent glucose uptake through AMPK and 265 
Pl3K/Akt mediated increase in GLUT4 translocation to plasma membrane [40]. 266 
 267 
A chronic low-grade inflammation is a main feature of diabetic insulin resistance, hence 268 
improving the insulin sensitivity may suppress the inflammation. In this study, our 269 
participants were generally healthy, therefore the observed association between plasma 270 
catechins and CRP may stem from more direct effect of tea catechins on the inflammation.  271 
Indeed, in intervention studies, tea catechins, especially EGCG, have been reported to reduce 272 
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CRP levels in healthy men and among male smokers [41, 42]. In addition, EGCG is known to 273 
be inversely associated with CRP in a large cohort study of healthy adults [43]. 274 
 275 
A major limitation of this study was the small number of (n = 57) participants. The sample 276 
size was set to detect moderate associations so as not to miss any biologically important 277 
correlation. Multivariate regression analysis accounting for confounding factors was not 278 
feasible. Nevertheless, to minimize variability due to gender, the present study investigated 279 
women only, given the differences in metabolic disease risk profiles between genders, and 280 
especially higher smoking prevalence and alcohol consumption by Japanese men. A large-281 
scale study comparing catechin levels between men and women is worthwhile to pursue in 282 
the future. Moreover, because the subject recruitment was conducted in a relatively 283 
constrained area, further replication studies are required to validate our findings. Finally, our 284 
urinary samples were assessed without normalization against creatinine, which should be 285 
taken into account when interpreting the results.  286 
 287 
In conclusion, our study provided the first report on the association between elevated levels 288 
of plasma and urinary green tea catechins and improved plasma lipid profile, as well as their 289 
negative association with some biomarkers of diabetes. Consistent with the hypothesis, the 290 
preliminary evidence suggests that plasma and/or urinary concentrations of tea catechins may 291 
be an alternative indicator of green tea consumption in lowering CVD and diabetes risk.  292 
 293 
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Table 1. Characteristics of participants 
 
Characteristic means ± SD 
(n = 57) 
Age (years) 52.0 ± 8.0 
Weight (kg) 54.2 ± 9.0 
Body mass index (kg/m
2
) 22.5 ± 4.1 
Body fat percentage 24.6 ± 6.4 
Waist circumference (cm) 72.0 ± 9.5 
Hip circumference (cm) 89.5 ± 7.1 
Waist-hip-ratio 0.80 ± 0.1 
Systolic blood pressure (mmHg) 116.8 ± 12.1 
Diastolic blood pressure (mmHg) 71.9 ± 9.5 




Table 2. Association between plasma and urinary green tea catechins and 
cardiovascular disease biomarkers 
 
Plasma catechins Total EGCG EGC ECG EC 
Triglyceride -0.29** -0.26** -0.23* -0.33** -0.13 
LDL-Cholesterol -0.28** -0.22* -0.25* -0.27** -0.22* 
HDL-Cholesterol 0.18 0.15 0.09 0.18 0.06 
Body fat % -0.08 -0.09 -0.11 -0.09 -0.14 
BMI -0.05 -0.04 -0.01 -0.06 -0.08 
Urinary catechins Total EGCG EGC ECG EC 
Triglyceride -0.19 -0.33** -0.23* -0.33** -0.09 
LDL-cholesterol -0.15 -0.15 -0.19 -0.18 -0.04 
HDL-cholesterol 0.11 0.13 0.11 0.18 0.04 
Body fat % -0.18 -0.25* -0.20 -0.30** -0.07 
BMI -0.11 -0.18 -0.17 -0.20 0.03 
 
Values are Spearman’s correlation coefficients (n = 57) with * indicates p < 0.1, ** p < 0.05. 
EGCG: (-)-epigallocatechin-3-gallate; EGC: (-)-epigallocatechin; ECG: (-)-epicatechin-3-
gallate; EC: (-)-epicatechin; LDL: low density lipoprotein; HDL: high density lipoprotein; 





Table 3. Association between plasma and urinary green tea catechins and diabetes 
biomarkers 
 
Plasma catechins Total EGCG EGC ECG EC 
Fasting glucose -0.15 -0.16 -0.09 -0.178 -0.07 
HbA1c -0.24* -0.23* -0.17 -0.30** -0.25* 
Insulin 0.09 0.10 0.10 0.05 0.14 
CRP -0.28** -0.25* -0.36** -0.24* -0.34** 
Urinary catechins Total EGCG EGC ECG EC 
Fasting glucose -0.01 -0.05 -0.05 -0.02 0.07 
HbA1c -0.24* -0.23* -0.24* -0.26* -0.15 
Insulin 0.01 0.02 -0.01 -0.01 0.09 
CRP -0.14 -0.17 -0.16 -0.16 -0.09 
 
Values are Spearman’s correlation coefficients (n = 57) with * indicates p < 0.1, ** p < 0.05. 
EGCG: (-)-epigallocatechin-3-gallate; EGC: (-)-epigallocatechin; ECG: (-)-epicatechin-3-
gallate; EC: (-)-epicatechin; HbA1c: glycated haemoglobin; CRP: C-reactive protein 
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Limit of detection 
(nM) 
EC 289.1 203.0 10 
ECG 441.1 289.2 10 
EGC 305.1 124.9 30 
EGCG 457.1 168.9 10 
 
EGCG: (-)-epigallocatechin-3-gallate; EGC: (-)-epigallocatechin; ECG: (-)-epicatechin-3-
gallate; EC: (-)-epicatechin 
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Supplementary Table 2. Concentration of green tea catechins in urine and plasma 
 
Urine (nM/100ul) means ± SD (n = 57) 
EGCG 12.39 ± 11.80 
EGC 1007.89 ± 2015.31 
ECG 1.90 ± 2.29 
EC 98.70 ± 183.47 
Plasma (nM/100ul) means  ± SD (n = 57) 
EGCG 34.93 ± 46.20 
EGC 31.27 ± 46.77 
ECG 9.23 ± 12.37 
EC 6.43 ± 10.16 
 
EGCG: (-)-epigallocatechin-3-gallate; EGC: (-)-epigallocatechin; ECG: (-)-epicatechin-3-
gallate; EC: (-)-epicatechin 
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Supplementary Table 3. Plasma levels of cardiovascular disease and diabetes 
biomarkers 
 
Biomarker means ± SD (n = 57) 
LDL-cholesterol (mg/dl) 130.25 ± 30.65 
HDL-cholesterol (mg/dl) 71.21 ± 17.19 
Triglyceride (mg/dl) 101.82 ± 94.09 
Fasting blood glucose (mg/dl) 94.18 ± 36.55 
Insulin (μU/ml) 4.82 ± 3.13 
HbA1c (%) 5.44 ± 0.96 
CRP (mg/dl) 0.10 ± 0.21 
 
LDL: low density lipoprotein; HDL: high density lipoprotein; HbA1c: glycated haemoglobin; 






Figure 1. Representative HPLC-MS/MS peak chart of standard 
The HPLC-MS/MS peak chart obtained from standards of (-)-epigallocatechin-3-gallate 
(EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin-3-gallate (ECG), (-)-epicatechin (EC), 
and ethyl gallate (EG) is shown with each corresponding retention time. 
 
 
Figure 2. Example scatter plot of Spearman correlation analysis  
Spearman’s rank correlation analysis was performed to investigate the association between 
plasma and urinary catechins and disease biomarkers (n = 57). Example scatter plots show 
the associations between plasma and urinary total catechin and plasma triglyceride. 
 
